Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1807 1
1808 2
1818 1
1826 1
1844 1
1912 1
1931 1
1932 2
1937 1
1940 1
1944 1
1945 2
1946 4
1947 9
1948 10
1949 16
1950 28
1951 27
1952 19
1953 20
1954 18
1955 15
1956 19
1957 16
1958 18
1959 17
1960 12
1961 16
1962 15
1963 12
1964 22
1965 22
1966 16
1967 12
1968 20
1969 27
1970 18
1971 29
1972 23
1973 23
1974 30
1975 28
1976 31
1977 53
1978 34
1979 30
1980 36
1981 53
1982 51
1983 60
1984 75
1985 83
1986 102
1987 83
1988 90
1989 122
1990 97
1991 113
1992 123
1993 116
1994 132
1995 122
1996 115
1997 122
1998 149
1999 129
2000 158
2001 150
2002 144
2003 163
2004 177
2005 171
2006 198
2007 185
2008 210
2009 210
2010 248
2011 280
2012 313
2013 283
2014 277
2015 305
2016 268
2017 262
2018 272
2019 258
2020 313
2021 341
2022 309
2023 256
2024 99

Text availability

Article attribute

Article type

Publication date

Search Results

7,904 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L, Richter A, Carroll M, Carr EJ, Beale R, Rea D, Parry H, Pirrie S, Lim Z, Satsangi J, Dunachie SJ, Cook G, Miller P, Basu N, Gilmour A, Hodgkins AM, Evans L, Hughes A, Longet S, Meacham G, Yong KL, A'Hearne MJ, Koh MBC, Burns SO, Orchard K, Paterson C, McIlroy G, Murray SM, Thomson T, Dimitriadis S, Goulston L, Miller S, Keillor V, Prendecki M, Thomas D, Kirkham A, McInnes IB, Kearns P; OCTAVE-DUO investigators. Goodyear CS, et al. Lancet Rheumatol. 2024 May 8:S2665-9913(24)00065-1. doi: 10.1016/S2665-9913(24)00065-1. Online ahead of print. Lancet Rheumatol. 2024. PMID: 38734019
Lack of p38 activation in T cells increases IL-35 and protects against obesity by promoting thermogenesis.
Nikolic I, Ruiz-Garrido I, Crespo M, Romero-Becerra R, Leiva-Vega L, Mora A, León M, Rodríguez E, Leiva M, Plata-Gómez AB, Alvarez Flores MB, Torres JL, Hernández-Cosido L, López JA, Vázquez J, Efeyan A, Martin P, Marcos M, Sabio G. Nikolic I, et al. Among authors: martin p. EMBO Rep. 2024 May 10. doi: 10.1038/s44319-024-00149-y. Online ahead of print. EMBO Rep. 2024. PMID: 38730210
Deciphering complexity in Pd-catalyzed cross-couplings.
Clarke GE, Firth JD, Ledingham LA, Horbaczewskyj CS, Bourne RA, Bray JTW, Martin PL, Eastwood JB, Campbell R, Pagett A, MacQuarrie DJ, Slattery JM, Lynam JM, Whitwood AC, Milani J, Hart S, Wilson J, Fairlamb IJS. Clarke GE, et al. Among authors: martin pl. Nat Commun. 2024 May 10;15(1):3968. doi: 10.1038/s41467-024-47939-5. Nat Commun. 2024. PMID: 38729925 Free PMC article.
Towards the Targeted Protein Degradation of PRMT1.
Martin PL, Pérez-Areales FJ, Rao SV, Walsh SJ, Carroll JS, Spring DR. Martin PL, et al. ChemMedChem. 2024 May 9:e202400269. doi: 10.1002/cmdc.202400269. Online ahead of print. ChemMedChem. 2024. PMID: 38724444
"It gave me a sense of achievement and a sense of purpose"-a qualitative study of patient experiences of a virtually supervised exercise program for adults with advanced cancer and cachexia.
Bland KA, France-Ratcliffe M, Krishnasamy M, Nandi A, Parr EB, Martin P, Cormie P, van Loon LJC, Zopf EM. Bland KA, et al. Among authors: martin p. Support Care Cancer. 2024 May 3;32(5):325. doi: 10.1007/s00520-024-08526-y. Support Care Cancer. 2024. PMID: 38700712 Clinical Trial.
Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma.
Mei M, Tsai NC, Palmer J, Armenian S, Chen R, Rosen S, Forman S, Popplewell L, Kwak L, Martin P, Maddocks K, Bond D, Herrera AF. Mei M, et al. Among authors: martin p. Clin Lymphoma Myeloma Leuk. 2024 Apr 10:S2152-2650(24)00148-4. doi: 10.1016/j.clml.2024.03.013. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38693037
7,904 results